IGlarLixi

Phase 3Small molecule

Sanofi

IGlarLixi is one of 50 small molecule programs targeting Type 2 Diabetes. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesCompleted

Metabolic Dysfunction-Associated Steatotic Liver DiseaseActive, not recruiting

ALSRecruiting

Type 2 DiabetesPhase 3

Completed

Metabolic Dysfunction-Associated Steatotic Liver DiseasePhase 3

Active, not recruiting

ALSPhase 3

Recruiting

Competition

Competitive Landscape

171 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

IGlarLixi

Sanofi

Phase 3

5 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 6

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 7

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 8

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Routine Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Type 2 Diabetes

NCT07307235

Clinical

Trials by Indication[1]

Type 2 Diabetes5 trials

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

Completed·UUniversity of Campania Luigi Vanvitelli·Phase 4·NCT04196231·258 enrolled

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

Unknown status·—·Phase 4·NCT04893148·40 enrolled

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Completed·PPopulation Health Research Institute·Phase 3·NCT03130426·161 enrolled

Show 2 more trials

Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA

Completed· Sanofi logo

Sanofi·Approved·NCT06716424·105 enrolled

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial

Recruiting·SShanghai Zhongshan Hospital·Approved·NCT07307235·1,316 enrolled

ALS1 trial

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Recruiting· Sanofi logo

Sanofi·Phase 4·NCT06671587·678 enrolled

AIN1 trial

Effects of Insulin Glargine and Lixisenatide on the Brain

Terminated·UUniversity Hospital Tuebingen·Phase 4·NCT03881995·1 enrolled

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus With Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized Controlled Trial

Active, not recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Approved·NCT07274644·36 enrolled

Unspecified1 trial

INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi

Unknown status·IInstitute for Clinical and Experimental Medicine·Phase 4·NCT04945070·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for IGlarLixi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IGlarLixi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IGlarLixi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

IGlarLixi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Type 2 Diabetes5 trials

ALS1 trial

AIN1 trial

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News